dc.creator | Sebastianelli A., Morselli S., Spatafora P., Liaci A., Gemma L., Zaccaro C., Vignozzi L., Maggi M., McVary K.T., Kaplan S.A., Chapple C., Gravas S., Serni S., Gacci M. | en |
dc.date.accessioned | 2023-01-31T09:54:52Z | |
dc.date.available | 2023-01-31T09:54:52Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.23736/S2724-6051.20.04099-0 | |
dc.identifier.issn | 27246051 | |
dc.identifier.uri | http://hdl.handle.net/11615/78873 | |
dc.description.abstract | BACKGROUND: The aim of this study was to assess the impact of tadalafil 5 mg/die plus tamsulosin 0.4 mg/die combination therapy on lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), according to presence vs. absence of metabolic syndrome (MetS). METHODS: Seventy-five consecutive men presenting with ED and LUTS were enrolled. Patients were divided into two groups according to MetS presence. All subjects were treated with combination therapy for 12 weeks. Patients were re-evaluated after treatment with uroflowmetry and post-void residual volume (PVR), International Prostate Symptoms Score (IPSS), IPSS Quality of Life (QoL), overactive bladder questionnaire (OAB-q) and International Index Erectile Function-5 (IIEF-5) Score. RESULTS: After enrollment, 50 patients were included: 31 (62.0%) with MetS and 19 (38.0%) without MetS. At baseline, patients without MetS showed a significantly better IPSS, IIEF and OAB-q, as compared to those with MetS. After 12 weeks of combination therapy LUTS, ED and flowmetry significantly improved in both groups (P<0.001). The improvement after 12 weeks was similar between groups in all parameters (P>0.05), except for ∆OAB-q that was significantly better for patients with MetS (P=0.028). Nevertheless, total IPSS, all IPSS subscores and OAB-q were significantly better at 12 weeks in men without MetS (P<0.05). Despite IIEF-5 was significantly different at baseline, after 12 weeks of combination therapy, erectile function was similar in men with or without METS: 16.3±3.8 vs. 17.7±4.7 (P=0.238). No serious adverse event (AE) was reported, and complications were comparable between groups (P>0.05). CONCLUSIONS: Patients with MetS have worse LUTS and ED profiles. However, tadalafil plus tamsulosin combination treatment provided them a similar ED profile and a greater relief of overactive bladder (OAB) symptoms at the end of the trial. Combination therapy had the same safety profile in men besides MetS. Further randomized controlled trials are needed. © 2020 EDIZIONI MINERVA MEDICA. | en |
dc.language.iso | en | en |
dc.source | Minerva Urology and Nephrology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124497255&doi=10.23736%2fS2724-6051.20.04099-0&partnerID=40&md5=3d4201959e8680167735f7d1f0484158 | |
dc.subject | high density lipoprotein cholesterol | en |
dc.subject | tadalafil | en |
dc.subject | tamsulosin | en |
dc.subject | triacylglycerol | en |
dc.subject | phosphodiesterase V inhibitor | en |
dc.subject | tadalafil | en |
dc.subject | tamsulosin | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | aspermia | en |
dc.subject | backache | en |
dc.subject | bedtime dosage | en |
dc.subject | bladder obstruction | en |
dc.subject | clinical article | en |
dc.subject | clinical outcome | en |
dc.subject | controlled study | en |
dc.subject | diastolic blood pressure | en |
dc.subject | digital rectal examination | en |
dc.subject | disease assessment | en |
dc.subject | dizziness | en |
dc.subject | dyspepsia | en |
dc.subject | erectile dysfunction | en |
dc.subject | food intake | en |
dc.subject | headache | en |
dc.subject | human | en |
dc.subject | International Index of Erectile Function | en |
dc.subject | International Prostate Symptom Score | en |
dc.subject | lower urinary tract symptom | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | metabolic syndrome X | en |
dc.subject | middle aged | en |
dc.subject | overactive bladder questionnaire | en |
dc.subject | postvoid residual urine volume | en |
dc.subject | quality of life | en |
dc.subject | randomized controlled trial | en |
dc.subject | rhinopharyngitis | en |
dc.subject | systolic blood pressure | en |
dc.subject | treatment outcome | en |
dc.subject | triacylglycerol blood level | en |
dc.subject | ultrasound | en |
dc.subject | uroflowmetry | en |
dc.subject | vital sign | en |
dc.subject | waist circumference | en |
dc.subject | complication | en |
dc.subject | double blind procedure | en |
dc.subject | erectile dysfunction | en |
dc.subject | lower urinary tract symptom | en |
dc.subject | metabolic syndrome X | en |
dc.subject | prostate hypertrophy | en |
dc.subject | Double-Blind Method | en |
dc.subject | Erectile Dysfunction | en |
dc.subject | Humans | en |
dc.subject | Lower Urinary Tract Symptoms | en |
dc.subject | Male | en |
dc.subject | Metabolic Syndrome | en |
dc.subject | Phosphodiesterase 5 Inhibitors | en |
dc.subject | Prostatic Hyperplasia | en |
dc.subject | Quality of Life | en |
dc.subject | Tadalafil | en |
dc.subject | Tamsulosin | en |
dc.subject | Edizioni Minerva Medica | en |
dc.title | Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome | en |
dc.type | journalArticle | en |